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Inducible Hsp70 (Hsp70i) is overexpressed in a wide
spectrum of human tumors, and its expression cor-
relates with metastasis, poor outcomes, and resis-
tance to chemotherapy in patients. Identification of
small-molecule inhibitors selective for Hsp70i could
provide new therapeutic tools for cancer treatment.
In this work, we used fluorescence-linked enzyme
chemoproteomic strategy (FLECS) to identify HS-
72, an allosteric inhibitor selective for Hsp70i. HS-
72 displays the hallmarks of Hsp70 inhibition in cells,
promoting substrate protein degradation and growth
inhibition. Importantly, HS-72 is selective for Hsp70i
over the closely related constitutively active Hsc70.
Studies with purified protein show HS-72 acts as
an allosteric inhibitor, reducing ATP affinity. In vivo
HS-72 is well-tolerated, showing bioavailability and
efficacy, inhibiting tumor growth and promoting sur-
vival in a HER2+ model of breast cancer. The HS-
72 scaffold is amenable to resynthesis and iteration,
suggesting an ideal starting point for a new genera-
tion of anticancer therapeutics targeting Hsp70i.
INTRODUCTION
The heat shock protein 70 (Hsp70) family members have broad
chaperone functions in cells that include folding of nascent pro-
teins, refolding of misfolded proteins, removal of protein com-
plexes, and control of regulatory proteins (Evans et al., 2010).
These functions are driven by ATP hydrolysis in the N-terminal
nucleotide-binding domain (NBD) of the Hsp70s. The Hsp70s
are evolutionary conserved across species, and there are eight
mammalian family members (Hunt and Morimoto, 1985). The
inducible form of Hsp70 (Hsp70i) (also called Hsp72, Hsp70-1,
and HspA1A/HspA1B) is present in low or undetectable levels1648 Chemistry & Biology 21, 1648–1659, December 18, 2014 ª2014in unstressed normal cells; however, expression levels rapidly in-
crease in response to cellular stresses such as heat shock, viral
infection, or transformation. Deletion of its immediate paralog,
the constitutive heat shock protein cognate 70 (Hsc70) is devel-
opmentally lethal, whereas deletion of Hsp70i results in sterility
of male mice but no other overt phenotype (Dix et al., 1996).
Hsp70i and Hsc70 are highly related, sharing 90% sequence
identity, with most of the amino acid variability confined to the
NBD. There is greater sequence divergencewith respect to other
Hsp70 familymembers (50%–80% identity), especially within the
NBD (Daugaard et al., 2007). The close sequence similarity be-
tween Hsp70i and Hsc70 has contributed to past difficulties in
separating the two proteins’ functions, both pharmacologically
and with RNAi approaches.
Overexpression of Hsp70i has been observed in several can-
cers, including breast, prostate, and colon, and this is thought
to aid in resistance to apoptosis as well as to anticancer treat-
ments (Shu and Huang, 2008). Hsp70i inhibits both intrinsic
and extrinsic apoptosis pathways. This occurs by preventing
tumor-necrosis-factor-related apoptosis-inducing ligand forma-
tion of the death-induced signaling complex through inhibition
of death receptors 4 and 5, as well as by inhibiting events in
mitochondrial-mediated apoptosis (Guo et al., 2005). In the
latter case, Hsp70i prevents Bax translocation to the mitochon-
dria, preventing release of cytochrome c, an apoptosis-inducing
factor (Yang et al., 2012). Additionally, Hsp70i mediates both
caspase-dependent and independent apoptotic pathways by
binding Apaf-1, blocking recruitment of procaspase-9 to the
apoptosome, and by inhibition of JNK, respectively (Beere
et al., 2000; Massey et al., 2010). Hsp70i also protects cancer
cells from oncogenic stress induced by upregulation of specific
oncogenes such as HER2. Increased expression of Hsp70i
correlates with resistance to chemotherapy and radiation and
therefore poor clinical outcomes by providing cancer cells a
route to survive and proliferate in the presence of noxious stimuli
such as hypoxia or denatured protein aggregates. These data
have led to the proposal that cancer cells are dependent on
Hsp70i for survival (Goloudina et al., 2012). This hypothesis
is supported by Hsp70i depletion studies in which tumor cellElsevier Ltd All rights reserved
Figure 1. Recombinant GFP-Hsp70i Is
Readily Captured on g-Phosphate-Linked
ATP Resin and Competitively Released
with ATP/ADP, Consistent with Nucleo-
tide-Induced Conformational Changes
(A) GFP-Hsp70i was bound to g-phosphate-linked
ATP-sepharose and then eluted with the indicated
[ATP] or [ADP] (mean ± SEM).
(B and C) The solution structures shown in (B) and
(C) suggest a mode of binding in which the GFP-
fusion protein first recognizes the immobilized
nucleotide in its open apo state. The protein closes
around the immobilized ATP but cannot hydrolyze
the g phosphate. The presence of free Mg2+ATP,
in contrast to ADP, however, enables rapid turn-
over and release of the bound protein. (B) Struc-
ture of Hsp70 (E. coli, DnaK) in the ATP-bound
conformation (PDB 4B9Q) and (C) in the ADP-
bound apo conformation (PDB 2KHO). NBD
highlighted in blue, linker domain highlighted in
green, and SBD highlighted in red. ATP repre-
sented in (B) as ball-and-stick model.
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Discovery of an Allosteric Hsp70i Inhibitordeath and sensitivity to chemotherapeutic drugs were evident,
whereas nontumorigenic cell lines were unaffected by Hsp70i
depletion (Nylandsted et al., 2002).
From a drug discovery perspective, Hsp70i presents a number
of challenges, not the least of which being its close sequence
identity with Hsc70. Specific, physiological substrates of
Hsp70i are poorly defined, and high-throughput assays based
on chaperone or trafficking activities are limited (Kang et al.,
2008). The crystal structure of the E. coli Hsp70, Dnak, shows
the protein in either a closed nucleotide bound state or open
unbound state (Qi et al., 2013). In the closed conformation,
the bound nucleotide shows little solvent accessibility to the
surface, limiting access to diffusible small-molecule inhibitors.
In cells, Hsp70smay be reminiscent of small G proteins, in which
the nucleotide-binding pocket is always occupied, undergoing
guanosine triphosphate (GTP)/guanosine diphosphate (GDP) ex-
change upon activation, again limiting small-molecule accessi-
bility. In the case of Hsp70i, the protein has high affinity for
ADP, which is likely exchanged with ATP through allosteric
regulation (Powers et al., 2010). The chaperone activities of
Hsp70i are also regulated by the C terminus in cooperation
with cochaperones, such as Hsp40, Hip, Hop, CHIP, and Bag1
(Tavaria et al., 1996). Crystallographic and nuclear magnetic
resonance studies have shown that these cochaperones induce
altered conformational states (Evans et al., 2010). Because of
these many complications, most Hsp70 inhibitors have either
failed to discriminate between various Hsp70 family members
or perform poorly in vivo (Massey, 2010).
To identify Hsp70 inhibitors that discriminate Hsp70i from
Hsc70 and other family members, we used a fluorescence-
linked enzyme chemoproteomic strategy (FLECS) to screen an
in-house library of 3,379 purine-like molecules (Carlson et al.,
2013). The screen identified HS-72, a highly selective allostericChemistry & Biology 21, 1648–1659, December 18, 2014 ªinhibitor of Hsp70i. HS-72 bears all the
hallmarks of an Hsp70 inhibitor in cell
models of breast cancer and in a cell cul-
ture model of Huntington’s disease. Themolecule is well tolerated and is bioavailable in mice and shows
efficacy in the mouse mammary tumor virus (MMTV)-neumouse
model of breast cancer. These data indicate that the HS-72 scaf-
fold is an excellent starting point for development of highly selec-
tive inhibitors of Hsp70i.
RESULTS
FLECS Screening Yields Highly Selective Hsp70i
Interactors
For screening of Hsp70i inhibitors by FLECS, GFP-Hsp70i was
expressed in human embryonic kidney 293 (HEK293) cells, ex-
tracts prepared, incubated directly with g-phosphate-linked
ATP-sepharose, and then eluted with ATP or ADP (Figure 1A).
These studies demonstrated that the GFP-fusion protein has a
fully functional nucleotide-binding pocket and that binding oc-
curs in a reversible manner. Based on the crystal structure of
the Hsp70 homolog DnaK with bound ATP, showing limited sol-
vent accessibility, recovery of the fusion protein on g-linked ATP
resin was at first surprising (Figure 1B). This is because the g-
phosphate oxygen on the immobilized ATP is tethered to poly-
ethylene glycol (PEG), which is expected to sterically hinder
Hsp70i binding. We therefore propose that the fusion protein is
recovered through binding Hsp70i in the apo or ADP-bound
form, which is subsequently driven into the ATP-bound confor-
mation when exposed to the g-linked ATP resin (Figure 1C).
Once bound, the protein is retained because of an inability to
hydrolyze the PEG-linked phosphate. The dramatic differences
in elution between ATP compared to ADP shown in Figure 1A
are consistent with this hypothesis. Once bound, exposure to
low mM [Mg2+ATP] enables the protein to turn over and be
released. In contrast, mM [ADP] was required to compete the
bound fusion protein from the immobilized nucleotide. These2014 Elsevier Ltd All rights reserved 1649
Figure 2. Heatmaps Showing Summary of
Results of Screening of Hsp70i by FLECS
and the Relative Selectivity of Hits against
Other Purinome Members
(A) FLECS identified 197 primary hits from a
collection of 3,379 purine-like molecules (color
scale: dark red, strong signal to light yellow,
background).
(B) The relative selectivity of all hits against Hsp70i
is shown comparedwith other distinct members of
the broader purinome screened against the same
library by FLECS including ACC1, DAPK3, PIMK 1,
PIMK 2, PIMK 3, Hsp90, TRAP 1, FASN, IRAK 2,
PfPK9, NEK9, DENV NS5, AMPK g, and a subunit
(color scale: light blue, selective; dark red,
nonselective).
(C) Structure of lead molecule HS-72.
See also Figures S1 and S2.
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identify selective inhibitors of Hsp70i that either act competitively
at the ATP-binding site or allosterically to regulate nucleotide
binding.
Assembly of our focused library, consisting of 3,379 purine-
like compounds, was described previously (Carlson et al.,
2013). Figure S1 (available online) describes FLECS, illustrating
how individual compounds are screened in parallel against the
ATP medium charged with GFP-Hsp70i. Briefly, GFP-Hsp70i is
expressed in HEK293T cells and crude cell lysate is then added
to the ATP resin. Following several wash steps, the bound GFP-
Hsp70i is plated along with the compounds from the library in 96-
well filter plates with ATP serving as a positive control or with
buffer to serve as a negative control. The lysates were eluted
from the filter plate onto a catch plate by centrifugation, and
the fluorescence of the eluates was measured. Those com-
pounds that disrupted the Hsp70i-ATP association resulted in
an increased fluorescence signal over the buffer-only samples.
The primary screen identified 197 hits from the library, which
were then sorted by their specificity toward GFP-Hsp70i over
other purinome members that had also been screened against
the same chemical library by FLECS (Figures 2A and 2B). The
compounds that were active in multiple assays were removed
from consideration. Next, the presence of GFP-Hsp70i in the el-
uates from the 197 primary hits was determined by western blot.
This reduced the collection to 60 compounds and also elimi-
nated autofluorescent false-positive molecules (Figure S2A).
Next, we tested the ability of the 60 compounds for elution of
native Hsp70 from the ATP resin using pig bladder extracts, a
rich source of native Hsp70i (Figure S2B). This reduced the final
collection to 22 diverse structures (0.65%of the library), showing
selectivity toward both recombinant human and native mamma-
lian Hsp70i (Figure S2C).1650 Chemistry & Biology 21, 1648–1659, December 18, 2014 ª2014 Elsevier Ltd All rights reIdentification of a Caspase-
Activating Cell-Permeable
Compound that Targets Hsp70i
To further narrow the number of com-
pounds, we first tested the 22 hits for their
ability to activate caspase-3 and cas-
pase-7 in various cancer cells, which isa hallmark of Hsp70i inhibition (Beere, 2001). Of the compounds
tested, (S)-N-(1-propyl-1H-benzo[d]imidazol-2-yl)-1-(pyrazin-2-
yl)piperidine-3-carboxamide (HS-72) was most robust, inducing
caspase activation in a dose-dependent manner (Figure S2D).
Other compounds were either less potent in this assay or were
cell impermeable and were not pursued herein. Furthermore,
caspase activation by HS-72 was reproducible across several
cancer cell lines at 6 hr and 24 hr in a dose-dependent manner
(Figures S2E and S2F). As a second test, we examined the effect
of HS-72 on the expression of Akt and HER2, two known client
proteins of Hsp70i, in BT474 breast cancer cells. Figure S2G
shows dose-dependent reduction in Akt and HER2 with HS-72.
HS-72 Specifically Targets Hsp70i over Other Members
of the Hsp70 Superfamily
To test the selectivity of the HS-72 scaffold against the broader
purinome, HEK293T cell extracts or pig bladder tissue lysates
were applied to the ATP resin and eluted with HS-72, as
described for FLECS. The eluates were characterized by SDS-
PAGE, silver stain, and mass spectrometry (MS) analysis. Silver
stain analysis for both HEK293T cells and pig bladder lysates
confirmed elution of native Hsp70i and showed only a few
nonspecifically eluted proteins, indicating that HS-72 has a
high degree of specificity within the wider purinome (Figures
S3A and S3B). To more-thoroughly determine the specificity of
HS-72 for Hsp70i, the HEK293T eluates were also analyzed for
other Hsp70 family members Hsc70, Grp78, and Grp75, as
well as Hsp90 by western blot. This showed selective elution of
Hsp70i by HS-72, with ATP serving as a positive control,
showing elution of Hsp70 family members and Hsp90 (Fig-
ure S3C). Next, we synthesized an affinity resin using the
HS-72 scaffold. HEK293T cell lysate was applied to the resin
and subjected to several washes. To confirm selectivity of theserved
Figure 3. The HS-72 Scaffold Is Highly Selective for Hsp70i over the Constitutively Active Hsc70 and the Wider Purinome
Cleavable HS-72 affinity resin was synthesized and mixed with HEK293T crude cell lysate ± free HS-72. Following washing, sodium dithionite (25 mM) was used
to cleave the ligand and the eluted proteins subjected to SDS-PAGE.
(A) Western blot analysis for Hsp70i reveals Hsp70i binding to the affinity resin, and this interaction is blocked by free HS-72.
(B) Western blot against Hsc70 shows no binding to the resin.
(C) Silver staining also demonstrates selectivity of the immobilized ligand for Hsp70i. Hsp90 recovery was noncompetitive with respect to HS-72 and therefore
nonspecifically bound to the media.
See also Figure S3.
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Discovery of an Allosteric Hsp70i InhibitorHS-72 affinity resin for Hsp70i, free HS-72 was incubated with
lysate to inhibit Hsp70i binding to the affinity resin. The linker
on the resin was cleaved using sodium dithionite, and the sam-
ples were subjected to SDS-PAGE and analyzed by western
blot, silver stain, and mass spectrometry. When probing for
Hsp70i by western blot, the HS-72 affinity resin binds Hsp70i,
and free HS-72 is able to block this interaction (Figure 3A).
Importantly, when probing for the closely related Hsp70 family
member, Hsc70, the HS-72 affinity resin does not pull down
Hsc70 (Figure 3B). This indicates that the HS-72 scaffold is
highly selective for the inducible Hsp70 over the constitutively
active Hsc70. Furthermore, silver stain and MS analysis reveals
the HS-72 affinity resin pulls down Hsp70i, and this association
is blocked with free HS-72, with very few nonspecific interac-
tions (Figure 3C). Whereas Hsp90 is also pulled down, as shown
in Figure 3C, this is a nonspecific interaction with the media
itself because the association is not blocked by free HS-72.
These studies identified HS-72, a small molecule that can selec-
tively discriminate Hsp70i from other members of the Hsp70
superfamily.
HS-72 Is an Allosteric Inhibitor of Hsp70
Because the initial isolate of HS-72 was a racemic mixture, the
molecule was resynthesized in its R and S enantiomeric forms.
Figure S4A shows the S enantiomer more effectively elutes
GFP-Hsp70i from ATP resin than the R enantiomer (referred to
herein as HS-71). To characterize the S and R enantiomers in
more detail, we tested their effects on the thermal stability of pu-
rified Hsp70i and Hsc70 (Figures 4, S4B, and S4C). The Ther-
mofluor assay is used to show direct binding of a small molecule
as measured by a change in melting temperature (Tm) (Cum-
mings et al., 2006). In general, ATP competitive inhibitors impart
a large degree of thermal stability to purine-binding proteins
because of the number of potential contacts within the nucleo-
tide-binding pocket (Cummings et al., 2006). For example, Fig-
ure 4A shows that HS-10, an inhibitor of Hsp90, increases the
Tm of this chaperone from 50
C to 60.5C. Similarly, incubationChemistry & Biology 21, 1648–165of purified Hsp70i with ATP or ADP increased the Tm by 4
C or
5C (Figure 4B). However, when we repeated the study with HS-
72, the Tm of Hsp70i decreased in a dose-dependent manner
(Figure 4C). Conversely, HS-71 had no effect on Tm of Hsp70i,
indicating that any effects observed with HS-72 cannot be ex-
plained by artifacts in the Thermofluor assay, such as nonspe-
cific ionic interactions or hydrophobic binding or fluorophore
quenching (Figure 4D). The effect of HS-72 on thermal stability
was more obvious when the experiment was repeated in the
presence of ATP, whereas HS-71 had no effect on Tm (Figures
4E and 4F). Significantly, HS-72 had no destabilizing effect on
the ADP-bound form (Figure 4G). Moreover, detergents had
no effect on the ability of HS-72 to destabilize Hsp70i, elimi-
nating the possibility of nonspecific protein aggregation (Fig-
ure S4D). Furthermore, when HS-72 was tested with purified
Hsc70 in the Thermofluor assay, the compound failed to trigger
a significant shift in Hsc70 Tm in the presence or absence of ATP
(Figures 4H and 4I). This further supports the selective nature of
HS-72 for Hsp70i. Taken together, these data suggest that,
although HS-72 is directly binding and selective for Hsp70i, its
site(s) of interaction are unlikely to be in the ATP-binding pocket.
This hypothesis is consistent with data showing that HS-72
does not directly inhibit ATP hydrolysis in single-turnover assays
with Hsp70i (Figure 4J). Based on our Thermofluor data, the
most likely mechanism of HS-72 destabilization is via allosteric
binding, which reduces the protein’s affinity for ATP. To explain
HS-72’s action in this context, we hypothesize that, upon
binding to the ATP-bound state, the molecule induces large
conformational changes, breaking a number of internal stabiliz-
ing contacts between the NBD and C-terminal domain. This
mechanism of action is also reminiscent of a small-molecule
allosteric inhibitor that decreases the Tm of RGS4 (Blazer
et al., 2010).
Hsp70i C306D Mutation Perturbs HS-72 Binding
Miyata et al. (2012), using site-directed mutagenesis, showed
that Hsp70i C306 is a potential allosteric regulatory site within9, December 18, 2014 ª2014 Elsevier Ltd All rights reserved 1651
Figure 4. Thermal Stability and Single-Turn-
over Assays Reveal HS-72 Is an Allosteric
Inhibitor of Hsp70i
(A) Control study with HS-10 (Hsp90 inhibitor) in-
creases the Tm of Hsp90 by 10.5
C.
(B) ATP and ADP increase the Tm of Hsp70i in a
dose-dependent manner.
(C) HS-72 decreases the Tm of Hsp70i by 0.1
C
and 0.5C at 10 mM and 100 mM, respectively,
indicating an allosteric effect (p < 0.001 versus
control).
(D) HS-71 does not change Hsp70i Tm.
(E) ATP increases the Tm of Hsp70i by 3
C,
whereas HS-72 decreases ATP-bound Hsp70i Tm
0.5C and 1C at 10 mM and 100 mM, respectively
(p < 0.001 versus ATP).
(F) HS-71 does not change the Tm of the ATP-
bound Hsp70i.
(G) ADP increases the Tm of Hsp70i by 2.5
C,
whereas HS-72 does not change the Tm of ADP
Hsp70i.
(H and I) HS-72 does not change Tm of
Hsc70 ± ATP.
(J) HS-72 does not reduce Hsp70 ATPase activity
in the presence or absence of cochaperone, Hlj1.
Hsp70 + DMSO and Hsp70 + Hlj1 + DMSO indi-
cated by dashed lines. Hsp70 + HS-72 is in green,
and Hsp70 + Hlj1 + HS-72 is in red. Hlj1 + DMSO is
indicated by dashed lines with squares.
(K and L) HS-72 does not change Tm of the Hsp70i
C306D mutant ± ATP.
Mean ± SEM. RFU, relative fluorescence units.
See also Figure S4.
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Hsp70 family members, including Hsc70. Consistent with this
earlier work, Figures 4K and 4L show that the Tm of the Hsp70i
C306D mutant was insensitive to HS-72, either in the presence
or absence of ATP. The lack of effect of HS-72 on the thermal
stability of Hsp70i C306D suggests that the molecule interacts
either directly with C306 or that mutation of this residue results1652 Chemistry & Biology 21, 1648–1659, December 18, 2014 ª2014 Elsevier Ltd All rights rein a conformational change that renders
the HS-72-binding site inaccessible.
HS-72 Allosteric Interaction
Induces a Conformational Change
in Hsp70i
In an attempt to gain some insight how
HS-72 might be interacting with Hsp70i,
we conducted a docking study of HS-72
with the crystal structure of the human
NBD of Hsp70i containing AMP-pnp us-
ing the SwissDock program (Grosdidier
et al., 2011). Docking revealed 37 clus-
ters, which were distributed between
two binding sites on either side of the
bound ATP analog, further supporting
an allosteric mechanism of action (Fig-
ures 5A and 5B). Along with the docking
studies, we used partial proteolysis to
identify potential sites of interactions.Partial proteolysis, visualized through silver stain, reveals a pro-
found difference in the proteolytic pattern of Hsp70i in the pres-
ence of HS-72, which indicates that HS-72 induces a conforma-
tional change in Hsp70i over several time points (Figures 5C, 5D,
and S5A). Furthermore, MS analysis of the proteolytic pattern
revealed specific residues that are protected from trypsin diges-
tion upon inhibitor binding. Specifically, after 24 hr, peptidesserved
Figure 5. Molecular Modeling and Native
Protein Digestion Studies Support HS-72
as an Allosteric Inhibitor of Hsp70i
(A and B) Two 180 views of Hsp70i NBD (PDB
2E8A), highlighting two potential binding sites of
HS-72 (sticks) from docking studies. Views also
show residues identified that are protected from
trypsin digestion (highlighted in red). AMP-pnp is
shown as a space-filling molecule in the center.
Visualized using Chimera.
(C and D) SDS-PAGE and silver stain showing re-
sults of native digests of Hsp70i ± HS-72 and ATP
or ADP at 2 hr (C) and 24 hr (D), revealing differ-
ences in digestion patterns. Full-length Hsp70
(black arrow) and tryptic fragments (blue arrows).
See also Figure S5.
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treated with HS-72 but absent in the samples lacking HS-72 (Fig-
ures 5D and S5B–S5D). We propose that the conformational
change induced by HS-72 results in sequences 141–155, 326–
342, and 518–533 to be protected from digestion.
Collectively, these studies yield some insight as to the poten-
tial mode of HS-72 interaction with Hsp70i. The molecular dock-
ing studies reveal two putative binding sites that are distinct from
the sequences that were protected from trypsin digestion (Fig-
ures 5A and 5B). Therefore, it is likely that HS-72 is inducing a
conformational change in Hsp70i that alters surface exposure
to trypsin and therefore protects the identified sequences from
trypsin digestion.
To further investigate HS-72 sites of interaction, HS-72 was
tested in combination with VER-15508 (VER) or pifithrin-m
(PES) by Thermofluor. There was an increase in Hsp70i Tm with
VER, consistent with previous work by Massey et al. (2010)
showing binding of this compound in the active site of the
NBD. When testing HS-72 and VER in combination, there was
no observed synergistic or additive effect on Hsp70i Tm in the
absence or presence of ATP, indicating that these molecules
do not target Hsp70i at the same sites (Figures S5E and S5F).
This further supports an allosteric binding site of HS-72, because
VER is known to bind the active site in the NBD. When testing
PES alone, there was no dose-dependent effect on Hsp70i Tm
(Figure S5G). Furthermore, there was no synergistic or additive
effect when testing HS-72 and PES in combination, indicatingChemistry & Biology 21, 1648–1659, December 18, 2014 ªdifferent binding sites on Hsp70i (Figures
S5G and S5H). This indicates that HS-72
is not targeting the Hsp70i substrate-
binding domain (SBD), the primary site
of PES binding (Leu et al., 2009).
HS-72 Induces Cellular Protein
Aggregation
A hallmark of Hsp70i inhibition in cells is
induction of protein aggregation, which
was assayed using a cell culture model
of Huntington’s disease. In this model,
the PC12 rat neuronal cell line contains
74-glutamine repeats from exon 1 of hu-
man Huntington, fused to GFP (httQ74-GFP) (Wyttenbach et al., 2001). The httQ74-GFP is expressed
stably and is inducible through a doxycycline-regulated pro-
moter. We found an induction in protein aggregates in the pres-
ence of HS-72 compared with untreated controls, shown by an
increase in the insoluble associated pellet fraction (Figure 6A).
Quantification of these bands shows a 50% increase in the insol-
uble associated pellet fraction in the HS-72-treated samples
compared to untreated controls (Figure S6A).
HS-72 Inhibits Cancer Cell Proliferation
Upregulation of Hsp70i has been implicated in tumorigenicity in
breast and prostate cancers (Goloudina et al., 2012; Shu and
Huang, 2008). To determine if HS-72 discriminates between
various cell lines, we carried out proliferation assays. Figures
6B–6G show that the inhibitor has potent antiproliferative activity
against the tumorigenic breast and prostate lines, whereas the
nontumorigenic lines continued to proliferate in the presence of
HS-72. There was a significant inhibition (p < 0.001) of prolifera-
tion in all tumorigenic cell lines tested (Figures 6B–6E). In
contrast, the nontumorigenic MCF10A cells continue to grow
at all concentrations, whereas the RWPE1 cells were only in-
hibited at the highest concentration tested (Figures 6F and 6G).
HS-71 treatment results in a less-potent effect on proliferation
compared to HS-72, consistent with biochemical studies (Fig-
ures S6B and S6C).
To test if HS-72 acts synergistically with Hsp90 inhibitors, we
tested the effect of the Hsp90 inhibitor HS-10 in combination2014 Elsevier Ltd All rights reserved 1653
Figure 6. HS-72 Inhibits Hsp70i Activity in a Huntington’s Cell Model and across Multiple Tumorigenic Cell Lines
(A) HS-72 induces protein aggregation in a cell culture model of Huntington’s disease, as shown by an increase in httQ-GFP protein associated with the insoluble,
pellet (P), fraction compared to the soluble (S) fraction.
(B–G) HS-72 inhibits proliferation of (B) BT474, (C) MCF7, (D) SkBr3 breast cancer cell lines, and (E) LnCaP prostate cancer cell lines. In contrast, nontumorigenic
(F) MCF10A and (G) RWPE1 cells are insensitive to HS-72.
(H and I) HS72 and the Hsp90 inhibitor HS10 show synergism in inhibiting cancer cell proliferation in (H) SkBr3 and (I) MCF7 cells. Mean ± SEM. *p < 0.05; ***p <
0.001.
See also Figure S6.
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Discovery of an Allosteric Hsp70i Inhibitorwith HS-72 on the degradation of HER2 and Akt, which are clas-
sified as substrates or clients of Hsp70i and Hsp90, respectively.
In the presence of HS-72, there is degradation of HER2 and Akt
that is consistent with previous results (Figure S2G). HS-10 alone
also induced degradation of HER2 and Akt, as well as increased
Hsp70 protein levels as expected, due to the negative regulatory
role that Hsp90 has on heat shock transcription factor 1. In com-
bination, the levels of HER2were completely abolished and there
was significant Akt degradation (Figure S6D). Next, we deter-
mined the effect of inhibitor combination on SkBr3 and MCF7
cell proliferation. Increasing amounts of HS-72 in addition to
the HS-10 treatment resulted in an additive effect, potently inhib-
iting the proliferation of both cell linesmore so than HS-72 or HS-1654 Chemistry & Biology 21, 1648–1659, December 18, 2014 ª201410 alone (Figures 6H and 6I). These results add to the growing
evidence that Hsp90 andHsp70i inhibitor combinations are likely
to have great therapeutic utility in the clinic (Guo et al., 2005;
Powers et al., 2009).
HS-72 Is Bioavailable In Vivo and Reduces Tumor
Growth in a Spontaneous Mouse Mammary Tumor
Model
Prior to testing the efficacy of HS-72 in vivo, we performed a pre-
liminary experiment to assess dose-dependent effects in wild-
typemice. Healthy wild-typemice were dose escalated biweekly
for 35 days, and no adverse events, reduction in body weight,
or altered behavior were observed up to 30 mg/kg (mpk)Elsevier Ltd All rights reserved
Figure 7. Pharmacokinetic, Distribution, and Efficacy Studies with HS-72 in Healthy Mice and MMTV-neu Mice
(A–C) LC-MS analysis of plasma, kidney, and liver following i.p. injection, 20 mg/kg (mpk), at the indicated time points over 24 hr show HS-72 has high degree of
bioavailability in healthy mice.
(D) HS-72 promotes reduction in tumor volume in MMTV-neu mice treated i.p. with HS72 biweekly (BiW) at 20 mpk (n = 7) compared to animals receiving no
treatment (n = 26) with a significant decrease in tumor volume (p < 0.05) at 21 days. Linear regression analysis comparing the slopes of the HS-72 tumor volume
versus no treatment tumor volume is trending toward significance (p = 0.08).
(E) The median survival of animals treated i.p. with HS-72 20 mpk BiW or HS-72 20 mpk qd increased by 6 days and 13 days, respectively, compared to animals
receiving no treatment. One set of control animals was used for multiple treatments, yielding more control animals than treated animals.
(A–D) Mean ± SEM. See also Figure S7.
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following HS-72 treatment in wild-type mice. Mice that were
treated with HS-72 showed no effect on complete blood count,
no effect on kidney function, and no effect on liver function
compared to control mice (Figures S7B–S7D). These data indi-
cate that HS-72 is not toxic to wild-type mice. A limited pharma-
cokinetic (PK) study was also performed using wild-type mice,
analyzing and quantifying HS-72 in the plasma, liver, and kidney.
Each sample was spiked with an internal standard, HS-156,
which is a close structural analog to HS-72, and analyzed by
liquid chromatography (LC)-MS (Figure S7E). The ratio of the ex-
tracted ion chromatogram comparing HS-72 to HS-156 was
plotted on a standard curve to quantify [HS-72] present in each
sample (Figures S7F–S7H and supplemental information avail-
able at http://figshare.com/articles/Supplemental_Information_
2_for_Identification_of_a_Novel_Allosteric_Small_Molecule_
Inhibitor_of_the_Inducible_Form_of_Heat_Shock_Protein_70/
1209606). Figure 7A indicates that HS-72 is exponentially
cleared from the plasma (T1/2 elimination = 0.4 ± 0.1 hr; n =
3; SEM), reaching 0.07 ± 0.03 mmol/ml (n = 3; SEM) by
5 min post-intraperitoneal (i.p.) injection, clearing to 0.002 ±
0.0002 mmol/ml (n = 3; SEM) by 8 hr, with only trace amounts
detectable (<10 nmol/ml) by 24 hr. In kidney, HS-72 reached
0.43 ± 0.08 mmol/g tissue (wet weight [w.w.]; n = 3; SEM)
at 5 min and by 24 hr was retained at 0.02 ± 0.004 mmol/gChemistry & Biology 21, 1648–165(w.w.; n = 3; SEM; Figure 7B). In contrast, in liver, HS-72 uptake
peaked by 8 hr at 2.26 ± 0.50 mmol/g (w.w.; n = 3; SEM) and was
slowly cleared to 0.51 ± 0.11 mmol/g (w.w.; n = 3; SEM) by 24 hr
(Figure 7C). These findings showplasmaHS-72 present at signif-
icant levels for at least 8 hr post i.p. and that HS-72 has a high
degree of tissue bioavailability. In all three compartments, the
parent MS ion of 365.2 Da was detected intact, with no evidence
of rapid metabolism. The finding that HS-72 is absorbed to high
[mM] levels following i.p. injection at 20 mpk, particularly in liver
as well as kidney without adverse event, suggests the molecule
is well tolerated in vivo.
The apparent safety and bioavailability of HS-72 allowed us to
test the efficacy of HS-72 to reduce tumor growth in the MMTV-
neu breast cancer model. In this model, HER2 is overexpressed
under the transcriptional control of the mouse mammary tumor
virus promoter/enhancer, leading to spontaneous development
of mammary tumors (Taneja et al., 2009). To confirm that HS-
72 would have efficacy in the MMTV-neu mouse model, HS-72
was tested in the NF639 cell line, which is derived from themam-
mary tumor of a MMTV-neu mouse. HS-72 was shown to
potently inhibit proliferation in a manner similar to previously
tested cell lines (Figure S7I). Furthermore, a synergistic effect
on cell proliferation was observed when testing HS-72 and
HS-10 in combination, thus highlighting the potential for com-
bination therapy in the MMTV-neu mouse model (Figure S7J).9, December 18, 2014 ª2014 Elsevier Ltd All rights reserved 1655
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20 mpk on a biweekly (BiW) schedule for 21 days. At 21 days,
there is a significant reduction (p < 0.05) in tumor volume in the
HS-72-treated mice compared to untreated mice (Figure 7D). A
linear regression analysis comparing the slopes of the HS-72 tu-
mor volume versus no treatment tumor volume is trending to-
ward significance (p = 0.08; Figure 7D). Furthermore, median
survival of animals increased by 6 days in mice treated with
HS-72 20 mpk BiW and by 13 days in animals treated with HS-
72 20 mpk daily dosing (qd) (Figure 7E). Collectively, these
studies show that the HS-72 scaffold has no overt toxicities, ex-
hibits tissue and tumor bioavailability, and demonstrates efficacy
in a spontaneous mouse mammary tumor model, even under
conservative biweekly dosing conditions. Our findings indicate
that further development of the HS-72 scaffold is warranted to
improve its potency and drug-like properties.
DISCUSSION
This work identifies a chemical scaffold, HS-72, that exhibits
specificity toward the inducible form of Hsp70, Hsp70i. Various
biochemical approaches demonstrated the selectivity of HS-72
toward Hsp70i over other Hsp70 family members, in particular
Hsc70. This includes selective elution from g-phosphate-linked
ATP resin, creation of a highly selective HS-72 affinity resin, a
selective thermo destabilizing effect in the presence of ATP
compared with Hsc70 and Hsp90, altered protease digestion
patterns in the presence and absence of the inhibitor, and
sensitivity to the S enantiomer over the R form HS-71. Our
studies also show that HS-72 has a distinct mechanism of ac-
tion in vitro by acting as an allosteric inhibitor of ATP binding, a
feature that certainly underlies its ability to discriminate Hsp70i
from other Hsp70 family members. This mode of action may
also explain HS-72 selectivity against the broader purinome,
because the molecule is not directly targeting the ATP-binding
pocket, which is also suggested by our molecular docking
studies.
In cells, HS-72 bears all the hallmarks associated with inhibi-
tion of Hsp70i. At the molecular level, this includes loss of
HER2 and Akt expression in breast tumor cells and formation
of protein aggregates in a cellular-based model of Huntington’s
disease. The inhibitor is also synergistic in combination with
Hsp90 inhibitors, as determined by monitoring HER2 and Akt
expression. In proliferation assays, HS-72 shows specificity to-
ward more-aggressive breast and prostate tumor cell lines,
consistent with the specific role of Hsp70i in mediating metasta-
tic progression in vivo. Importantly, HS-72 is well tolerated and
bioavailable in mice with no evidence of overt toxicity at high
doses. Collectively, these data suggest that HS-72 is an attrac-
tive starting point for amedicinal chemistry campaign to improve
the potency and pharmacological properties of the molecule.
With this longer-term aim in mind, we tested the efficacy of
HS-72 in the MMTV model, a murine model of spontaneous
breast cancer in humans (Taneja et al., 2009). On a conservative
biweekly administration cycle, HS-72 demonstrated significant
inhibition of tumor growth with evidence of improved survival.
Further, our PK study showed that plasma [HS-72] is maintained
at >20 mM for at least 8 hr, levels that reflect its potency against
various tumor cell lines in vitro.1656 Chemistry & Biology 21, 1648–1659, December 18, 2014 ª2014It is important to highlight that the HS-72 molecule was a raw
hit from the FLECS screen with no structure-activity relation-
ship (SAR) done to improve the compound. From a medicinal
chemistry perspective, the HS-72 scaffold is attractive and
we have shown that it is highly amenable to resynthesis; we
have synthesized a HS-72 affinity resin, and analogs can readily
be created to drive future SAR studies. The central piperidine
carboxamide scaffold that makes up the core of HS-72 is struc-
turally distinct from all other described Hsp70i inhibitors. Prior
inhibitors identified to target Hsp70s include NSC 630668-
R/1, VER, MAL3-101, MKT-077, PES, apoptozole, and YK5
(Powers et al., 2010; Rodina et al., 2013). There is considerable
structural diversity among these inhibitors, and generally, the
NBD domain has been favored for inhibitor development
(Powers et al., 2010). However, the polar interactions present
in the nucleotide-binding pocket and its affinity for ATP have
contributed to difficulties in selective inhibitor discovery (Mas-
sey, 2010). The full-length crystal structure of the nucleotide-
bound form shows that the nucleotide is completely enclosed,
making the accessibility of small inhibitors difficult (Figure 1B).
Importantly, none of the approaches adopted thus far have
been able to target specific Hsp70 family members, especially
Hsp70i from Hsc70. NSC 630668-R/1 inhibits ATPase activity
but does not discriminate Hsp70i from Hsc70 (Fewell et al.,
2001). VER shows broad specificity with other heat shock pro-
tein family members, largely because it is a nucleotide deriva-
tive. It also contains two potentially labile, perhaps by design,
benzyl groups (Massey, 2010). MAL3-101 has been shown to
compromise cochaperone-stimulated Hsp70 ATPase activity,
suggesting it is an allosteric regulator, although the exact bind-
ing site of this molecule remains unknown (Braunstein et al.,
2011). Like NSC 630668-R/1, MAL3-101 is quite large and
has a number of labile ester groups. MKT-077 targets the
NBD and inhibits proliferation in tumor cell lines; however, se-
vere renal dysfunction in patients was observed in phase I clin-
ical trials (Britten et al., 2000). PES has been shown to interact
with the SBD of both Hsc70 and Hsp70i and disrupt client pro-
tein interaction in vitro (Leu et al., 2009). However, recent evi-
dence suggests that the PES interaction with Hsp70 is through
nonspecific interactions (Schlecht et al., 2013). The molecule
promotes caspase-dependent cell death only in tumor cells,
suggesting some specificity to Hsp70i in vitro, although p53
binding has also been shown, which may explain its antitumor
actions (Leu et al., 2009). Moreover, MKT-077 and PES have
potential reactive groups that render them covalent modifiers,
which may contribute to side effects in vivo. YK5 is an allosteric
inhibitor of Hsp70, recently identified using modeling tech-
niques, but this molecule does not discriminate between
Hsp70i and Hsc70 (Rodina et al., 2013).
The FLECS assay employed in defining HS-72 is a simple
quantitative binding assay that offers an alternate approach to
defining inhibitors to enzymes/proteins that often seem intrac-
table to conventional high-throughput (HT) screens. Because
of its chaperoning and trafficking functions in vivo, Hsp70i is
a good example of such intractability. To date, few HT screens
have been designed that enable Hsp70i to be screened based
on its chaperone function or ATPase activity (Kang et al.,
2008; Rowlands et al., 2010; Wise´n and Gestwicki, 2008).
Although Hsp70i possesses ATPase activity, following turnover,Elsevier Ltd All rights reserved
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This means that competitive inhibitors acting at the ATP-bind-
ing site must bind with a very high affinity to displace the bound
nucleotide. In this respect, the Hsp70s are reminiscent of
small G proteins, which have nM affinity for both GTP and
GDP and are very difficult to drug directly. We propose that
Hsp70i is recovered on our ATP media as a result of the
ADP-bound or apo form being forced into and retained in the
active state when exposed to the immobilized nucleotide.
This enabled discovery of HS-72, which reduces the affinity of
Hsp70i for the immobilized ligand. We are currently exploring
the possibility of screening libraries containing molecules that
selectively block interactions with this media, rather than dis-
placing the bound protein through competitive or allosteric
means. Finally, the FLECS approach enabled our ability to
establish HS-72’s selectivity, both against the Hsp70 family
and the wider purinome. In our view, when targeting purine-uti-
lizing enzymes, the intrinsic selectivity of one’s lead scaffold
toward the enzyme of interest is a greater priority than initial
potency. This limits off-target liabilities that can be very difficult
to remove during lead optimization studies. For this reason, our
prioritization of HS-72 over other Hsp70i hits in our screen was
driven by the intrinsic nature of the scaffold toward the protein
over several other classes of purinome members screened
against the same library (Figure 2). The finding that HS-72 is
well tolerated in mice, reaching 2.26 mmol/g (w.w.) in the liver
without modification, is perhaps a testament to this prioritiza-
tion strategy.
SIGNIFICANCE
Hsp70i is generally recognized as a cutting edge drug target
for the development of a new generation of anticancer
drugs. However, drugging Hsp70i has proven extremely
challenging. Hsp70i undergoes ATP/ADP exchange, leaving
the nucleotide-binding pocket occupied at all times. This
presents a barrier to drug-like molecules that might act to
inhibit Hsp70i through direct competition with bound nucle-
otide. Additionally, Hsp70i shares close sequence identity
with other Hsp70 family members, in particular Hsc70, a
constitutively active Hsp70 family member, whose activities
are essential for normal cellular function. No groups to date
have defined inhibitors that can discriminate Hsp70i from
Hsc70. Screening by FLECS has identified a chemical scaf-
fold, called HS-72, that shows selectivity for Hsp70i over
the closely related Hsc70 as well as the broader purinome.
We show that HS-72 acts as an allosteric inhibitor of ATP
binding, a feature that underlies its ability to discriminate
Hsp70i from other Hsp70 family members. This discrim-
inates HS-72 from all previous inhibitors targeting purine-
utilizing proteins such as heat shock proteins or protein
kinases, which are generally ATP competitive. In mice, HS-
72 is well tolerated and bioavailable and shows no evidence
of overt toxicity at high doses. Furthermore, HS-72 shows
signs of efficacy in the MMTV model of HER2+ breast can-
cer. Whereas HS-72 is a raw hit from the FLECS screen,
our data suggest the HS-72 scaffold is an appealing starting
point for a medicinal chemistry campaign to improve its po-
tency and pharmacological properties in vivo.Chemistry & Biology 21, 1648–165EXPERIMENTAL PROCEDURES
FLECS Screen
A pEGFP-tagged Hsp70i was (plasmid 15215; Addgene) used in the FLECS
assay and was originally cloned by Evan Eisenburg (Zeng et al., 2004). ATP
used in the assay was purchased from Sigma, and a 200 mM stock was
prepared with low salt buffer (150 mM NaCl, 25 mM Tris [pH 7.5], and
60 mM MgCl2). The g-phosphate ATP sepharose was synthesized as
previously described and stored in low-salt buffer (Carlson et al., 2013).
FuGENE 6 transfection reagent (Roche) was used for transfection of
GFP-Hsp70i into HEK293T cells, following the manufacturer protocol. The
transfection ensued for 48 hr, upon which time the cells were harvested
and lysed in cell lysis buffer (150 mM NaCl, 50 mM Tris [pH 7.5], 1% Triton
X-100, 1 mM EDTA, 1 mM dithiothreitol [DTT], and one tablet Complete Mini
protease inhibitor [Roche]). Cell lysates were stored at 80C until further
use. Upon binding, the resin lysates were washed three times with high-
stringency wash buffer (1 M NaCl, 25 mM Tris [pH 7.5], 60 mM MgCl2,
and 1 mM DTT) and three times with low-stringency wash buffer
(150 mM NaCl, 25 mM Tris [pH 7.5], 60 mM MgCl2, and 1 mM DTT).
Next, the lysates were transferred to 0.2 mm polyvinylidene fluoride filter
96-well plate (Corning) sitting on top of a black flat-bottomed 96-well catch
plate (Corning). The plates were spun down using an Eppendorf Centrifuge
5810 at 2,000 rpm for 2 min.
Caspase 3/Caspase 7 Assay
The Amplite Fluorimetric Caspase3/7 Assay Kit (AAT Bioquest) was used per
the manufacturer’s instructions. Briefly, a fluorometric indicator, Ac-DEVD-7-
amino-4-methylcoumarin (AMC), was used to determine caspase activity.
Cleavage of AMC by caspases resulted in a fluorescent signal that can be as-
sessed at 440–460 nm with an excitation of 340–350 nm. Cells were seeded at
60,000 cells/well in a 96-well plate and treated with compound for the indi-
cated period of time. Diluted caspase 3 and caspase 7 assay solution was
added to each well and incubated at room temperature for 2 hr protected
from light, upon which time fluorescence was measured on the Victor X2 plate
reader (PerkinElmer).
Aggregation Assay
The PC12 rat neuronal cell line, which expresses Huntingtin exon 1 containing
74 glutamine repeats, is fused to GFP, and under the control of a doxycycline
promoter, was used. Cells were treated with HS-72 for 18 hr prior to a doxycy-
cline addition for 48 hr. The soluble and pellet fraction were then separated by
centrifugation at 14,000 rpm for 15 min, and both fractions were assayed for
httQ-GFP by solubilizing with SDS followed bywestern blotting with antibodies
against GFP.
Thermofluor Assay
SYPRO orange (Molecular Probes) was diluted 1:1,000 in 25 mM HEPES,
5 mM MgCl2, and 10 mM KCl (pH 7.5), and purified Hsp70i, Hsc70, Hsp70i
C306, or Hsp90 was then added to a final dilution of 0.04 mg/ml. Where indi-
cated, 0.001% or 0.01% Triton X-100 (Sigma) was also added. The indicated
compound or DMSOwas then added at the specified concentration, and each
sample was added as five replicates to a 384-well plate (BioRad). A melt curve
protocol (25C–90C, increasing 0.5C and a plate reading every 30 s) was run
on a CFX384 Touch Real-Time PCR Detection System (BioRad). To determine
the midpoint of the protein-unfolding transition or Tm, GraphPad Prisim4 was
used to normalize the melt curve and to calculate the first derivate of the
melt curve, with the steepest point of the slope being the Tm.
Docking Studies
HS-72was docked into the crystal structure of the Hsp70i NDB bound to AMP-
pnp (Protein Data Bank [PDB] 2E8A) using the SwissDock program. The re-
turned clusters were distributed between two binding sites. Chimera was
used to visualize the putative binding sites of HS-72 on the Hsp70i NBD.
Partial Proteolysis
Hsp70i (8 mg for SDS-PAGE analysis and 2 mg for mass spectrometry analysis)
was incubated with 1 mM ATP, 1 mM ADP, 100 mM HS72, 100 mM HS72 +
1 mM ATP, or 100 mM HS72 + 1 mM ADP for 30 min at room temperature.9, December 18, 2014 ª2014 Elsevier Ltd All rights reserved 1657
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and was quenched by addition of 25% trifluoroacetic acid for mass spectrom-
etry analysis or addition of 53 SDS loading buffer and boiling for SDS-PAGE
analysis at 2 hr or 24 hr. Gels were visualized by silver stain.
HS-72 In Vivo Efficacy Studies
MMTV-neumice, a HER2 overexpression breast cancer mousemodel in which
HER2 is under the transcriptional control of the mouse mammary tumor virus
promoter/enhancer, were treated with the indicated doses and dosing
schedule (Taneja et al., 2009). All doses were delivered through i.p. injections
using DMSO, and their tumors were calipered once weekly. The mice were
culled upon reaching tumor burden or if they expressed signs of toxicity as
per MP1U standard protocol.
For further details regarding the experimental procedures used in this work,
see the Supplemental Experimental Procedures section in the Supplemental
Information. PK study raw data files from LC-MS can be found in supplemental
information, located on figshare, and can be found here: http://figshare.com/
articles/Supplemental_Information_2_for_Identification_of_a_Novel_Allosteric_
Small_Molecule_Inhibitor_of_the_Inducible_Form_of_Heat_Shock_Protein_
70/1209606.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at http://dx.doi.
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